Trial Profile
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs 18F MNI 952 (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Diagnostic use
- 05 Oct 2017 Status changed from recruiting to completed.
- 22 Mar 2017 New trial record